References
- Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941;161:2465–74
- Almeida M, Iyer S, Martin Millan M, et al. Estrogen receptor alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest 2013;123:394–404
- Riggs BL. The mechanism of estrogen regulation of bone resorption. J Clin Invest 2000;106:1203–4
- Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for the prevention of osteoporosis after oophorectomy. Br Med J 1973;3:515–18
- Lindsay R, Hart DM. Effect of oestrogens on postmenopausal bone loss. Br Med J 1977;2:1087
- The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389–96
- de Villiers TJ. Estrogen and bone: have we completed a full circle? 8th Pieter Van Keep Memorial Lecture. Climacteric 2014;17(Suppl 2):4–7
- Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–41
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
- Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–38
- Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized trial. J Bone Miner Res 2006;21:817–28
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
- Shapiro S, de Villiers TJ, Pines A, et al. Risks and benefits of hormone therapy: has medical dogma now been overturned? Climacteric 2014;17:215–22
- Hough FS, Brown SL, Cassim B, et al. The safety of osteoporosis medication. S Afr Med J 2014;104:279–82
- de Villiers TJ, Gass MLS, Haines CJ, et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 2013;16:203–4
- de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
- Schumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA 2004; 291:2947–58
- Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement therapy in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728–35